Business Context and Reporting Period
This Form 8-K Current Report was filed by Bristol-Myers Squibb Company on April 2, 2004, regarding an event that occurred on April 1, 2004. The filing addresses a legal development concerning consolidated amended complaints in civil class action suits.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a legal event rather than financial performance data.
Material Changes
On April 1, 2004, the U.S. District Court for the Southern District of New York dismissed with prejudice the consolidated amended complaint against Bristol-Myers Squibb and other defendants. The suits alleged violations of federal securities laws related to:
- ImClone and its product, Erbitux.
- Accounting issues, including wholesaler inventory and sales incentives.
- The establishment of reserves.
- Accounting for certain assets and other sales.
Outlook, Risks, and Contingencies
While the dismissal is significant, the filing notes the following contingencies and risks:
- The court decision is subject to appeal.
- This dismissal is separate from other pending cases in New York State Court and federal court, including derivative and ERISA cases.
- Government investigations relating to similar matters remain pending.
Investor Verification Checklist
- Verify the status of the appeal regarding the April 1, 2004 dismissal.
- Review the status of separate pending cases in New York State Court and federal court (derivative and ERISA).
- Monitor ongoing government investigations related to the ImClone/Erbitux and accounting allegations.
- Consult Note 22 of the 2003 Annual Report on Form 10-K for detailed descriptions of the "Other Securities Matters."